Colorectal cancer
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old, male or female; 2. ECOG PS score is 0 ~ 2; 3. Patients with advanced colorectal cancer diagnosed by histology or cytology (mCRC); 4. Patients with unresectable recurrent solid tumors or who do not tolerate standard chemotherapy; 5. According to RECIST 1.1, at least one measurable target lesion exists; 6. Without intervention in the study, patients can use carillizumab combined with rigafinil in one or more lines; 7. According to imaging judgment (RECIST 1.1 standard), patients who had received the last anti-tumor regimen before enrollment or who had progressed during the treatment; 8. Sign informed consent and agree to collect clinical efficacy and information of patients;
Exclusion criteria
Exclusion criteria: 1. There is a third gap effusion (such as a large amount of hydrothorax and ascites) that cannot be controlled by drainage or other methods, and the clinical therapeutic effect cannot be evaluated; 2. Received radiotherapy, chemotherapy, surgery or other targeted therapy for colorectal cancer within 1 week before the first use of the study drug and did not progress from the previous treatment; 3. Patients with immunodeficiency (such as vitiligo, psoriasis, hypothyroidism requiring hormone replacement therapy, etc.) and patients allergic to experimental drugs; 4. Pregnant or lactating women, patients with fertility who are unwilling or unable to take effective contraceptive measures; 5. The investigator judges other situations that may affect the conduct of the clinical study and the judgment of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactJiang Haiping
The First Affiliated Hospital of Zhejiang University
Outcome results
None listed